title: MicroRNAs as potential diagnostic biomarkers in renal cell carcinoma.
abstract: Emerging evidence has suggested that microRNAs (miRNAs) may be promising novel biomarkers for the diagnosis of renal cell carcinoma (RCC). However, the results of current studies are still conflicting. Hence, we undertake the current meta-analysis to comprehensively assess the diagnostic potential of miRNAs in RCC. The bivariate meta-analysis model was employed to summarize the sensitivity, specificity, positive likelihood ratio (PLR), negative likelihood ratio (NLR), and diagnostic odds ratio (DOR). Summary receiver operating characteristic (SROC) curve and area under the curve (AUC) were used to evaluate the diagnostic accuracy. Subgroup analyses and meta-regression were used to explore the between-study heterogeneity. Deeks' funnel plot asymmetry test was used to test the potential of publication bias. All analyses were performed using STATA software (version 12.0). The pooled sensitivity and specificity of miRNAs for the diagnosis of RCC were 0.85 (95% confidence interval (CI), 0.77-0.90) and 0.84 (95% CI, 0.70-0.92). The value of AUC was 0.91 (95% CI, 0.88-0.93), suggesting that the diagnostic accuracy of miRNAs achieved a relatively high level. Furthermore, subgroup analyses showed that tissue-based miRNA assay is recommended to improve the diagnostic accuracy. In conclusion, the high degree of diagnostic accuracy suggests that miRNA in RCC patients may serve as next-generation biomarkers for detection of the disease. However, large-scale investigations and additional improvements are urgently needed to confirm our results and verify the feasibility of routine clinical utilization.
authors.affiliation: Department of Clinical Laboratory, Tieling Central Hospital, Tieling, 112000, China.
authors.forename: Yongqing
authors.initials: Y
authors.lastname: Gao
authors.forename: Hongmei
authors.initials: H
authors.lastname: Zhao
authors.forename: Ying
authors.initials: Y
authors.lastname: Lu
authors.forename: Haiyi
authors.initials: H
authors.lastname: Li
authors.forename: Gaobo
authors.initials: G
authors.lastname: Yan
mesh_terms: D019540:Area Under Curve; D014408:Biomarkers, Tumor / Q000235:genetics*; D002292:Carcinoma, Renal Cell / Q000175:diagnosis* / Q000235:genetics*; D016208:Databases, Factual; D006801:Humans; D007680:Kidney Neoplasms / Q000175:diagnosis* / Q000235:genetics*; D015201:Meta-Analysis as Topic; D035683:MicroRNAs / Q000235:genetics*; D008875:Middle Aged; D011379:Prognosis; D012372:ROC Curve
chemical_list: D014408:Biomarkers, Tumor; D035683:MicroRNAs
references.citation: Histopathology. 2004 Dec;45(6):593-602
references.pmid: 15569050
references.citation: Mol Cancer. 2009 Nov 14;8:102
references.pmid: 19912656
references.citation: Nat Rev Cancer. 2009 Apr;9(4):293-302
references.pmid: 19262572
references.citation: BMJ. 2001 Jul 21;323(7305):157-62
references.pmid: 11463691
references.citation: Ann Intern Med. 2011 Oct 18;155(8):529-36
references.pmid: 22007046
references.citation: Mol Cancer Res. 2003 Oct;1(12):882-91
references.pmid: 14573789
references.citation: Arch Pathol Lab Med. 2012 Apr;136(4):410-7
references.pmid: 22458903
references.citation: Hum Pathol. 2006 Apr;37(4):462-70
references.pmid: 16564922
references.citation: PLoS One. 2011;6(9):e25787
references.pmid: 21984948
references.citation: Br J Cancer. 2013 Nov 12;109(10):2646-53
references.pmid: 24129247
references.citation: Curr Opin Urol. 2007 Sep;17(5):303-8
references.pmid: 17762621
references.citation: J Clin Epidemiol. 2005 Sep;58(9):882-93
references.pmid: 16085191
references.citation: J Transl Med. 2012 Mar 22;10:55
references.pmid: 22440013
references.citation: Clin Chem. 2008 Mar;54(3):482-90
references.pmid: 18218722
references.citation: Exp Mol Pathol. 2013 Feb;94(1):115-20
references.pmid: 23064048
references.citation: Biochem Biophys Res Commun. 2011 Feb 11;405(2):153-6
references.pmid: 21232526
references.citation: Cancer Cell. 2006 Mar;9(3):189-98
references.pmid: 16530703
references.citation: Proc Natl Acad Sci U S A. 2011 Mar 22;108(12):5003-8
references.pmid: 21383194
references.citation: Proc Natl Acad Sci U S A. 2006 Feb 14;103(7):2257-61
references.pmid: 16461460
references.citation: CA Cancer J Clin. 2011 Mar-Apr;61(2):69-90
references.pmid: 21296855
references.citation: Cancer Treat Rev. 2007 May;33(3):299-313
references.pmid: 17329029
references.citation: Cancer Treat Rev. 2008 May;34(3):193-205
references.pmid: 18313224
references.citation: Eur Urol. 2010 Sep;58(3):398-406
references.pmid: 20633979
references.citation: N Engl J Med. 2005 Oct 27;353(17):1793-801
references.pmid: 16251535
references.citation: J Mol Diagn. 2012 Jul;14(4):385-92
references.pmid: 22580180
references.citation: Mod Pathol. 2009 Jun;22 Suppl 2:S2-S23
references.pmid: 19494850
references.citation: CA Cancer J Clin. 2008 Mar-Apr;58(2):71-96
references.pmid: 18287387
references.citation: J Clin Epidemiol. 2003 Nov;56(11):1129-35
references.pmid: 14615004
references.citation: Cell Res. 2008 Oct;18(10):997-1006
references.pmid: 18766170
references.citation: J Natl Cancer Inst. 2006 Sep 20;98(18):1331-4
references.pmid: 16985252
references.citation: Biochim Biophys Acta. 2008 Apr;1785(2):133-55
references.pmid: 18187049
references.citation: Int J Oncol. 2014 Jan;44(1):53-8
references.pmid: 24212760
references.citation: BMJ. 2004 Jul 17;329(7458):168-9
references.pmid: 15258077
references.citation: Proc Natl Acad Sci U S A. 2008 Jul 29;105(30):10513-8
references.pmid: 18663219
references.citation: Cell. 2004 Jan 23;116(2):281-97
references.pmid: 14744438
references.citation: PLoS One. 2008;3(11):e3694
references.pmid: 19002258
references.citation: Nat Rev Cancer. 2006 Nov;6(11):857-66
references.pmid: 17060945
references.citation: J Cancer Res Clin Oncol. 2010 Jun;136(6):855-62
references.pmid: 19921256
references.citation: Stat Med. 2010 May 30;29(12):1282-97
references.pmid: 19408255
references.citation: Br J Cancer. 2013 Aug 6;109(3):714-22
references.pmid: 23799849
references.citation: BMJ. 2003 Sep 6;327(7414):557-60
references.pmid: 12958120